Biotech Startup Vindicated in $460M Trade Secrets Litigation in Delaware

A federal jury trial in Delaware concluded with a favorable outcome for a California-based biotech startup facing accusations of trade secrets theft. The case was initiated by a competing entity that alleged the startup’s co-founder had wrongfully acquired confidential information related to cancer treatment antibodies. These claims were based on the co-founder’s role as an expert during an unrelated international arbitration. The jury’s decision has cleared the startup of any liability in this significant legal battle, potentially involving damages nearing $460 million. For further details, you can read the full context and analysis on Law360.